A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2013
At a glance
- Drugs Ulodesine (Primary) ; Allopurinol
- Indications Gout
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 16 Jul 2012 Primary endpoint identified as (CD4+-cell-count) as reported by ClinicalTrials.gov.
- 16 Jul 2012 Official Title amended as reported by ClinicalTrials.gov.